Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines

Hepatology

Volumn 32, Issue 3, 2000, Pages 482-490

  Yamanaka, Takenari ^a   Shiraki, Katsuya ^a   Sugimoto, Kazushi ^a   Ito, Takeshi ^a   Fujikawa, Katsuhiko ^a   Ito, Masaaki ^a   Takase, Koujiro ^a   Moriyama, Masami ^b   Nakano, Takeshi ^a   Suzuki, Atsushi ^c  

^a MIE UNIVERSITY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

^c Basic Technology Research Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 8; CELL RECEPTOR; DACTINOMYCIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REPORTER GENE;

EID: 0033839749     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.16266     Document Type: Article

References (52)

1. Apoptosis in cancer therapy: Crossing the threshold
2. Apoptosis. Its significance in cancer and cancer therapy
3. Mechanism and genes of cellular suicide
4. Apoptosis by death factor
5. Apoptosis in the pathogenesis and treatment of disease
6. Apoptosis signaling by death receptors
7. Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells
8. Expression of functional CD40 in human hepatocellular carcinoma
9. The Fas death factor
10. The antitumor function of tumor necrosis facior (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
11. Lethal effect of the anti-Fas antibody in mice
12. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
13. Identification and characterization of a new member of the TNF family that induces apoptosis
14. The receptor for the cytotoxic ligand TRAIL
15. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
16. TRAIL-R2 a novel apoptosis-mediating receptor for TRAIL
17. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
18. TRICK2, a new alternatively spliced receptor their transduces the cytotoxic signal from TRAIL
19. Characterization of two receptors for TRAIL
20. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
21. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
22. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
23. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
24. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL
25. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
26. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
27. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
28. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
29. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates in CD4 T cell killing of target cells
30. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
31. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NF-κB
32. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and cIAP2 to suppress caspase-8 activation
33. Suppression of TNF-α-induced apoptosis by NF-κB
34. An essential role for NF-κB in preventing TNF-α-induced cell death
35. Resistance to Fas-mediated apoptosis in human hepatoma cells
36. Resistance to Fas-mediated apoptosis: Activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP
37. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?
38. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild-type p53
39. Apoptosis in human hepatoma cell lines bY chemotherapeutic drugs via Fas-dependent and Fas-independent pathways
40. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo
41. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
42. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
43. The alteration of Fas receptor and ligand system in hepato-cellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
44. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
45. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas mediated cell death
46. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
47. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
48. KILLER/DR5 is a DNA damage inducible p53-regulated death receptor gene
49. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis
50. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells
51. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)
52. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand